Biosimilars or follow-on proteins are the terms given to biologicals that are similar to existing products presently in the market.

When patent on the original product has expired, it gives biotechnology companies the opportunity to market a similar product to that of the innovator.

The biosimilar drug market is growing faster than the proprietary pharmaceutical market. 

The market for SciGen's portfolio of products is increasing as the global trend of governments and other healthcare organizations are looking to use lower-priced generic and/or biosimilar pharmaceuticals to provide high quality healthcare.